The team

Our people are our strength

Executive leadership team

Itziar Canamasas, PhD.

Dr. Canamasas is a highly experienced pharmaceutical executive with a PhD in Tumor Genetics from the University of Mainz and studies at Harvard Business School and IMD Business School.

Gabriela Jiménez, PhD.
Co-Founder & COO

Dr. Jiménez has a PhD in Biomedicine from the University of Barcelona and studies BSM, EADA business school and IESE. She is experienced in business development, drug development and biomarker discovery.

Oriol Casanovas, PhD.
Co-Founder & CSO

Dr. Casanovas is an internationally renowned biomedical researcher with extensive knowledge and experience in basic and translational research focused on determining the consequences of adaptation and resistance to therapies against cancer.

Advisor team

Bart Huisken, MBA.
Co-Founder & Business Strategy

Richard Roberts, PhD.
Medicinal Chemistry Advisor

Todd Snowden
IVD Strategy Advisor

Research team

Our academic founders have played a key role in demonstrating that resistance to cancer therapy occurs in response to adaptive mechanisms of tumor cells.

We are part of the Program Against Cancer Therapeutic Resistance (ProCURE)

We research resistance mechanisms and tumor malignization

We are always looking for new talent to join our team